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Abstract
Background—High body mass index (BMI) is consistently linked to increased risk of colorectal 
cancer (CRC) for men, whereas the association is less clear for women. As risk estimates from 
observational studies may be biased and/or confounded, we conducted a Mendelian randomization 
study to estimate the causal association between BMI and CRC.
Methods—We used data from 10,226 CRC cases and 10,286 controls of European ancestry. The 
Mendelian randomization analysis used a weighted genetic risk score, derived from 77 genome-
wide association study identified variants associated with higher BMI, as an instrumental variable 
(IV). We compared the IV odds ratio (IV-OR) with the OR obtained using a conventional 
covariate-adjusted analysis.
Results—Individuals carrying greater numbers of BMI-increasing alleles had higher CRC risk 
(per weighted allele OR, 1.31; 95% confidence interval [CI], 1.10–1.57). Our IV estimation results 
support the hypothesis that genetically influenced BMI is directly associated with risk for CRC 
(IV-OR per 5 kg/m2, 1.50; 95% CI, 1.13–2.01). In the sex-specific IV analyses higher BMI was 
associated with higher risk of CRC among women (IV-OR per 5 kg/m2, 1.82; 95% CI, 1.26–2.61). 
For men, genetically influenced BMI was not associated with CRC (IV-OR per 5 kg/m2, 1.18; 
95% CI, 0.73–1.92).
Conclusions—High BMI was associated with increased CRC risk for women. Whether 
abdominal obesity, rather than overall obesity, is a more important risk factor for men requires 
further investigation.
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Impact—Overall, conventional epidemiologic and Mendelian randomization studies suggest a 
strong association between obesity and the risk of CRC.
Keywords
Colorectal cancer; Obesity; Epidemiology; Sex; Risk factors
Introduction
Observational studies consistently show that high body mass index (BMI) is associated with 
an increased risk of colorectal cancer (CRC) for men, whereas the magnitude of the 
association is less clear for women (1). Although these findings came from well designed 
and conducted epidemiologic studies, associations from observational studies could arise 
from bias and residual confounding and, therefore, may not necessarily reflect a causal 
relationship. First, the correlation between BMI and multiple other lifestyle and clinical 
factors suggests that adequate control for all potential confounding may be difficult. 
Conversely, over-adjustment in multivariable models can attenuate risk estimates towards 
the null and may explain the smaller associations reported for women (e.g., adjusting for 
menopausal hormone therapy) (2). Second, conventional epidemiologic analyses are often 
based on self-reports of participants’ weights and heights at one point in time and thus may 
be subject to misclassification from inaccurate reporting and insufficient follow-up to 
capture changes in measurements over time (e.g., men over-report height more so than 
women, and heavier women tend to under-report weight more so than heavier men (3, 4)). 
Finally, early stages of cancer may result in weight loss, and so measures of body weight 
reported within a few years of CRC diagnosis may introduce bias, a particular problem in 
case-control studies. As the latent period between high BMI and CRC risk is unknown, a 
measure that reflects typical lifetime BMI may counteract some of these limitations. 
Determining whether or not the association is causal is important as BMI could be a key 
target for primary prevention of CRC.
The use of genetic variants under the Mendelian randomization framework is one approach 
to exploring the possible causal nature of the observed associations between BMI and risk of 
CRC (5). Mendelian randomization uses instrumental variables (e.g., genetic variants that 
proxy for directly measured environmental risk factors) to make causal inferences about the 
relationship between a risk factor and an outcome and this approach can overcome issues of 
confounding, recall bias and reverse causality inherent in observational studies (5–7). First, 
because alleles are randomly allocated from parents to offspring during gamete formation, 
the association between the instrumental variable and the outcome is not confounded by 
environmental exposures. Second, genetic variants are measured reliably and are not 
affected by disease status. Furthermore, as those with the risk alleles have been essentially 
allocated randomly to higher levels of exposure across the lifecourse, genetic variation may 
more accurately reflect lifetime exposure compared with a single measurement. A potential 
limitation of Mendelian randomization arises however for highly complex traits whereby 
genetics may explain only a small fraction of the phenotypic variability. Many early 
Mendelian randomization studies used a single variant as an instrumental variable and, in 
the case described above, were unable to test the full spectrum of genetically influenced 
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phenotype. By using multiple genetic variants as instrumental variables, we can increase 
statistical power and improve the precision of the instrumental variable estimate (8).
We therefore conducted a Mendelian randomization study using a weighted genetic risk 
score, derived from 77 genetic variants associated with higher BMI, as an instrumental 
variable to reassess the observational estimates of the associations between BMI and CRC 
risk.
Materials and Methods
Our analyses included individual participant data and genetic material from 10,226 CRC 
cases and 10,286 population-based controls of European ancestry in the Genetics and 
Epidemiology of Colorectal Cancer Consortium (GECCO) and Colon-Cancer Family 
Registry (C-CFR). The 11 studies (6 cohort and 5 case-control) used in our analyses 
(Supplementary Table S1) have been described in detail previously (9) and include the 
Health Professionals Follow-up Study (HPFS) (10); Nurses’ Health Study (NHS) (11); 
Physician’s Health Study (PHS) (12); Prostate, Lung, Colorectal and Ovarian Cancer 
Screening Trial (PLCO) (13); VITamins and Lifestyle Study (VITAL) (14); Women’s 
Health Initiative (WHI) (15); the Colon-Cancer Family Registry (C-CFR) (16); Ontario 
Familial Colon Cancer Registries (OFCCR) (17); Diet, Activity and Lifestyle Survey 
(DALS) (18, 19); Postmenopausal Hormone Study (PMH-CCFR) (20); and Darmkrebs: 
Chancen der Verhütung durch Screening (DACHS) (21). To avoid confounding by 
population stratification, we used principal components analysis (HapMap II populations as 
reference) to restrict our analyses to individuals of European ancestry (22). Cases were men 
and women with primary invasive colorectal adenocarcinoma (International Classification of 
Diseases, 9th revision (ICD-9) codes 153.0–153.4, 153.6–153.9, and 154.0–154.1) and 
histologic confirmation (by medical records, pathologic reports, or death certificates) of 
CRC was performed for all studies. All participants provided written, informed consent and 
each study was approved by the relevant Institutional Review Boards.
Data on demographic and lifestyle factors were collected using in-person interviews or self-
completed questionnaires, and data were centrally harmonized as previously described (23). 
BMI was calculated as weight in kilograms divided by height in meters squared (kg/m2). 
Although the studies obtained participants’ weight (either self-report or measured) at 
different time points with respect to CRC diagnosis (Supplementary Table S1), we used 
weight that most accurately reflected usual adult weight prior to any disease-related weight 
loss. For the Mendelian randomization analysis, we used a weighted genetic risk score as an 
instrumental variable (IV) for BMI. A recent genome-wide association study (GWAS) 
conducted by the Genetic Investigation of Anthropometric Traits (GIANT) consortium 
involving over 300,000 individuals of European-descent identified 77 single nucleotide 
polymorphisms (SNPs) associated with BMI at genome-wide significance (e.g., P<5×10−8) 
(24). Genotype information on these 77 SNPs was used to construct the weighted genetic 
risk score. The GIANT GWAS for BMI found no evidence of non-additive effects among 
SNPs, thus we fit additive SNP effects. For each SNP, participants received a score of 0, 1 
or 2 for carrying zero (wild-type homozygous), one (heterozygous) or two (homozygous for 
the risk allele) alleles associated with higher BMI. For imputed SNPs, participants received 
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scores that ranged from 0 to 2. SNPs were externally-weighted in the score by the per-allele 
change in BMI (the increase in BMI per 1 additional risk allele) reported for that SNP in the 
GIANT GWAS for BMI (24). Details on genotyping and quality assurance/quality control 
have been previously published (9). Call rates were ≥98% and all selected SNPs were in 
Hardy-Weinberg Equilibrium among controls (P≥1×10−4).
Statistical analysis
Associations between potential confounders and CRC risk were assessed using chi-square 
tests and Student t-tests. Associations among potential confounders, the IV, and BMI were 
assessed in controls using linear regression, Student t-tests and analysis of variance.
All participants were analyzed using a single-model (pooled) approach with adjustment for 
study. For the IV analysis, we used the two-stage control function IV approach, with the 
genetic risk score as an IV for BMI, and assumed an additive model (25). First, we fit a 
linear regression model within controls to predict BMI from the IV, adjusted for study and 
the top three principal components of genetic ancestry. Next, we fit a logistic regression 
model with BMI as a predictor and CRC case-control status as the outcome using robust 
standard errors and adjusted for the residuals from the first step (25). The coefficient for 
BMI from the second-stage model is the causal estimate for BMI. In Mendelian 
randomization studies, the IV for the exposure of interest is considered sufficiently strong if 
the first-stage F-statistic exceeds 10 (26). For the conventional covariate-adjusted analysis, 
BMI was the variable of interest and odds ratios (OR) and 95% confidence intervals 
(95%CI) were estimated using unconditional logistic regression models. We conducted 
minimally adjusted analyses (models were adjusted for age, sex, and study) and fully 
adjusted analyses (models were additionally adjusted for smoking status, family history of 
cancer, history of diabetes, use of aspirin or non-steroidal anti-inflammatory drugs 
[NSAIDs], consumption of fruit, vegetables, processed meat, and red meat, and [women 
only] use of menopause hormone therapy). Variables were retained in the fully adjusted 
analyses if they were statistically significantly associated with CRC risk after mutual 
adjustment for other risk factors. Participants with missing data on covariates were included 
in the analyses using an additional category for missing values. We assessed whether the 
estimates obtained using conventional epidemiologic and IV methods were different using 
the Durbin form of the Durbin-Wu-Hausman statistic (27). Rejection of the null hypothesis 
(i.e., risk estimates for BMI from both analyses are equal) indicates that the OR from the 
conventional covariate-adjusted analysis differs from the OR from the IV approach. We 
examined potential statistical interaction between BMI and sex by including a multiplicative 
term in the model, and conducted additional analyses for the BMI-CRC association stratified 
by sex and cancer sub-site. Furthermore, we performed a sensitivity analysis excluding 
studies with self-reported weight. In a supplementary analysis, we examined the association 
between a weighted genetic risk score for waist-to-hip ratio (WHR), derived using 47 
variants associated with WHR adjusted for BMI (28), and CRC risk. Statistical significance 
was determined at α=0.05 and all tests for statistical significance were two-sided. Analyses 
were performed using Stata 12.0 (StataCorp, College Station, TX).
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The mean age of study participants was 63 years and 56% were women (Supplementary 
Table S1). Compared with controls, cases were more likely to smoke cigarettes, have a 
family history of cancer, and have diabetes and less likely to use aspirin or NSAIDs and 
(women only) menopausal hormones (Table 1). Cases consumed more red and processed 
meats on average than controls, but less fruit and vegetables. On average, cases (women: 
mean BMI, 27.0; standard deviation [SD], 5.4; men: mean BMI, 27.3; SD, 4.0) had 
statistically significantly higher BMI than controls (women: mean BMI, 26.2; SD, 5.0; men: 
mean, 26.5; SD, 3.7) (Supplementary Table S1). BMI was statistically significantly 
associated with age, sex, history of diabetes, use of aspirin/NSAIDs, consumption of fruit, 
processed meat, and red meat and, for women only, use of menopause hormone therapy 
(Supplementary Table S2).
The allele frequencies for each of the 77 SNPs were consistent across the 11 studies (data 
not shown). The IV was normally distributed (mean, 1.97; median, 1.97; SD, 0.2; minimum, 
1.37; maximum, 2.66) and the association between the IV and BMI was homogeneous 
across studies (test for heterogeneity, I2 = 0%; P = 0.45; Figure 1). From the pooled 
analysis, a one-unit increase in the IV was associated with a 3.23 kg/m2 (95% CI, 2.66–3.79) 
increase in BMI. The IV explained only 1.2% of the variance in BMI, but was a sufficiently 
strong instrument for BMI (F-statistic, 126). There were no associations of the IV with age, 
sex, smoking status, family history of cancer, consumption of fruit, vegetables, processed 
meat, and red meat or use of menopause hormone therapy (Supplementary Table S2). 
However, the IV was associated with history of diabetes, and we found a modest positive 
association between the IV and use of aspirin/NSAIDs (Supplementary Table S2).
Individuals with greater numbers of (weighted) BMI-increasing alleles (i.e., those with a 
higher weighted genetic risk score) were at increased risk for CRC (per weighted allele OR, 
1.31; 95%CI, 1.10–1.57; Supplementary Table S3). The IV analysis showed evidence that 
higher BMI was causally associated with increased risk of CRC (IV-OR per 5 kg/m2, 1.50; 
95% CI, 1.13–2.01). The IV point estimate was greater in magnitude than the point estimate 
from conventional covariate-adjusted analysis (minimally adjusted OR per 5 kg/m2, 1.18; 
95% CI, 1.15–1.22); however the 95% CIs overlapped and they were not statistically 
significantly different from one another (P-difference = 0.10). The findings were similar 
when we examined the BMI-CRC association by cancer sub-site in the colorectum (Table 
2). Additional adjustment for confounding did not change the estimates in the conventional 
analysis (Table 2) and, likewise, adjustment of the IV analysis for age, sex, history of 
diabetes, and use of aspirin/NSAIDs did not change the IV risk estimate for BMI (IV-OR 
per 5 kg/m2, 1.51; 95%CI, 1.13–2.02).
Using conventional methods, we found a statistically significant interaction between BMI 
and sex (CRC, Pinteraction<0.001; Colon, Pinteraction <0.001, Rectal, Pinteraction =0.02). The 
IV was a sufficiently strong instrument for BMI in stratified analyses for men (F-statistic, 
74.2; R2, 1.6%) and women (F-statistic, 60.5; R2, 1.0%). For men, there was no evidence 
that carriers of greater numbers of (weighted) BMI-increasing alleles were at increased risk 
for CRC and the risk estimate for CRC obtained from the IV analysis (IV-OR per 5 kg/m2, 
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1.18; 95% CI, 0.73–1.92) contained 95% CIs that included the null; however, the IV results 
were in the same direction as the estimate from conventional covariate-adjusted analysis 
(minimally adjusted OR per 5 kg/m2, 1.30; 95% CI, 1.23–1.38) and the two estimates were 
not statistically significantly different (P-difference = 0.70). In contrast, for women, carriers 
of greater numbers of (weighted) BMI-increasing alleles were at increased risk for CRC and 
the IV estimate for CRC risk (IV-OR per 5 kg/m2, 1.82; 95% CI, 1.26–2.61) was statistically 
significantly different from the estimate obtained from conventional covariate-adjusted 
analysis (minimally adjusted OR per 5 kg/m2, 1.14; 95% CI, 1.10–1.18; P-difference = 
0.01).
For men, the OR for BMI associated with CRC was greater in magnitude when the 
conventional covariate-adjusted analysis was restricted to those studies with measured 
height and weight (minimally adjusted OR per 5 kg/m2, 1.53; 95% CI, 1.33–1.76); there was 
no difference to the overall analysis for women (minimally adjusted OR per 5 kg/m2, 1.13; 
95% CI, 1.06–1.19).
In supplementary analyses, individuals with greater numbers of (weighted) WHR-increasing 
alleles were at increased risk for CRC (per weighted allele OR, 1.36; 95%CI, 1.08–1.73). In 
contrast to that seen for BMI, men with greater numbers of (weighted) WHR-increasing 
alleles were at increased risk for CRC, while there was no evidence that women carriers of 
greater numbers of (weighted) WHR-increasing alleles were at increased risk for CRC 
(Supplementary Table S3).
Discussion
Observational studies have consistently reported that high BMI is associated with increased 
risk of CRC; however, the magnitude of the BMI-CRC association may differ between men 
and women (1). The limitations of observational studies, such as residual confounding (e.g., 
by socio-economic status, smoking, alcohol, and other lifestyle and behavioral factors), 
reverse causation, and reporting bias, may contribute to the heterogeneity reported in 
previous studies. Using Mendelian randomization methods, we re-examined the association 
between BMI and CRC risk without the inherent limitations in observational studies and 
compared the IV and conventional estimates. Overall, we found that BMI was associated 
with CRC risk; however, the sex-specific associations in our study are in conflict with 
expectations based on the existing literature of the BMI-CRC association. For women, 
genetically influenced BMI was statistically significantly associated with risk of CRC and 
our findings suggest that BMI may confer greater risk of CRC than previously reported (1). 
On the other hand, for men, while the IV and conventional estimates of CRC risk associated 
with high BMI were not statistically significantly different, the IV for BMI was not 
associated with CRC risk for men.
Results from large meta-analyses indicate that the risk of CRC for men increases by 20–30% 
per 5 kg/m2 increase in BMI. For women, the magnitude of the association was lower in all 
studies (~10% increased risk per 5 kg/m2) and did not always reach statistical significance 
(1). Consistent with these results, in our conventional covariate-adjusted analysis, the 
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magnitude of the BMI-CRC association was substantially higher for men (32% increased 
risk per 5 kg/m2) than for women (15% increased per 5 kg/m2).
Using the Mendelian randomization approach, for women, we found evidence that 
genetically raised BMI was associated with increased risk of CRC. Importantly, the 
instrumental variable estimation for the BMI-CRC association for women was higher in 
magnitude than the risk estimate for BMI obtained from the conventional covariate-adjusted 
analysis. This suggests that the conventional risk estimate for women in our study, as well as 
those previously reported, may underestimate the true causal association between BMI and 
CRC risk for women. It is possible that previous estimates may have been biased toward the 
null if heavier women were more likely to under-report their weight than women with 
normal weight (3). This appears unlikely in our study as the results for women were similar 
between self-reported and measured BMI. There may also be sex-specific behavioral factors 
associated with BMI and CRC that may not be adequately measured and/or controlled for in 
a conventional epidemiologic analysis. This may explain why the risk estimates for BMI 
were different between self-reported and measured BMI for men, but not for women. It is 
also possible that the stronger effect in the IV analysis for women may be due to the IV for 
BMI reflecting genetic factors that express themselves early in life (e.g., BMI in childhood) 
and influence CRC risk more so than adult weight gain. An early effect of BMI on CRC risk 
for women may be plausible based on possible interactions between the different hormonal 
milieu associated with pre- and post-menopause. Mendelian randomization methods may 
better capture an early BMI effect on CRC risk for women than conventional epidemiologic 
methods. However, while our findings suggest that higher genetically influenced BMI is 
directly associated with increased CRC risk for women, the instrumental variable estimate is 
a valid test of the direction of the effect, and given the low variance explained, the exact 
magnitude of the effect could be in the range between the conventional estimates and our IV 
estimate.
For men, the conventional and IV estimates were not statistically significantly different from 
one another. However, the instrumental variable estimation gave evidence that genetically 
influenced BMI was not associated with CRC risk for men. It is unclear why the IV estimate 
for men was not statistically significant; however, it is unlikely that this was due to weak 
instrument bias as the IV was a strong instrument for BMI (F-statistic = 74.2). A possible 
explanation could be that the distribution of body fat, rather than total body fatness, may be 
an important predictor of CRC risk for men. In the supplementary analysis, we found that an 
IV for WHR was associated with CRC risk for men but not for women. Given that the IV 
was derived using SNPs associated with WHR adjusted for BMI, the two IVs in this study 
are largely distinct and these findings suggest that fat distribution may be important for CRC 
risk for men, while overall obesity may be more important for CRC risk for women.
The strengths of our study include the large sample size, centrally harmonized data, and the 
robust IV for the Mendelian randomization analysis. However, the findings from our 
Mendelian randomization study rely on three key assumptions, some of which are 
untestable: First, that the IV is associated with BMI. We constructed a weighted genetic risk 
score from 77 SNPs associated with higher BMI in an externally conducted genome-wide 
association study in order to maximize power (8) and provided evidence that the weighted 
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genetic risk score (the IV) is associated with BMI in our study (a sufficiently strong 
instrument with F-statistics >> 10). However, our IV analyses may have been underpowered 
as the IV explained less than 2% of total phenotypic variation for BMI, certainly a limitation 
for this study but one that is common when constructing IVs for highly complex traits – and 
seen in the original Locke paper (24) that established the relationship between the SNPs and 
BMI. The second assumption with Mendelian randomization is that the IV is associated with 
CRC only through its association with BMI. Although the biological effects of all the 
variants used in constructing the IV are not well known and this assumption cannot be tested 
directly, we feel that it is highly unlikely that a large subset of the 77 SNPs in the score 
would have pleiotropic associations with BMI and CRC. If the IV is associated with CRC 
risk through the same metabolic pathways (e.g., inflammation, oxidative stress, glucose/
insulin dysregulation) that are suspected to connect BMI to carcinogenesis, then this second 
assumption would still hold, since both the IV and BMI would be considered markers of 
altered metabolic (or related) risk factors. The final assumption is that the IV is not 
associated with factors that confound conventional observational associations. We found 
that the weighted genetic risk score was not associated with age, sex, smoking status, family 
history of cancer, diet, and other factors that may confound the BMI-CRC association in 
conventional covariate-adjusted analyses. The IV was associated with diabetes and use of 
aspirin/NSAIDs. The correlation with diabetes was expected since high BMI is such a strong 
risk factor for diabetes, and indeed, this is probably further evidence that the IV is an 
indicator of obesity-associated altered metabolism. The association with aspirin/NSAID-use 
was not expected a priori but might relate to prophylactic or treatment related use of aspirin 
regimens among heavier weight persons, or it might be due to chance. Nonetheless, 
inclusion of diabetes and aspirin/NSAID use in the IV analyses did not change the IV risk 
estimates for BMI. The majority of studies included in our analyses used self-reported 
weight and height and we showed that this may bias conventional estimates. Imprecision on 
genotypes from imputed SNPs is a limitation and may have resulted in loss of power in the 
instrumental variable analysis. A final limitation in this study is the lack of data on tumor 
molecular phenotype (29–31) and further research is warranted to answer this question.
Unlike estimates obtained from conventional covariate-adjusted analysis of observational 
data, the estimates from our IV analysis are not limited by confounding and/or bias. 
Therefore, they may be interpretable as a measure of the causal effect of BMI on CRC risk. 
Several mechanisms have been proposed to explain the association between high BMI and 
CRC risk, including insulin and the insulin-like growth factor system, adipokines (e.g., 
leptin, adiponectin), inflammation (e.g., C-reactive protein), oxidative stress, altered 
immunity, and steroid hormones, as discussed in recent comprehensive reviews (1, 32, 33).
Overweight and obesity are good targets for primary prevention of CRC, and men and 
women should be encouraged to maintain a normal BMI (18.5–25 kg/m2). Given the 
contrasting findings in this study for men and women, future studies are still needed to better 
understand the role of obesity (overall versus abdominal) in CRC carcinogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The association between the weighted genetic risk score (the instrumental variable) and 
body mass index (BMI) across the 11 participating studies in GECCO and C-CFR.
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